[Effect of HB 419--a new oral antidiabetic--on fat metabolism].
D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D000900:Anti-Bacterial Agents; D001786:Blood Glucose / Q000032:analysis; D046508:Culture Techniques; D003864:Depression, Chemical; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology; D005215:Fasting; D005223:Fats / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005990:Glycerol / Q000032:analysis; D006885:Hydroxybutyrates / Q000097:blood; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D051381:Rats; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D005223:Fats; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D014280:Triglycerides; D014508:Urea; D005990:Glycerol; D004837:Epinephrine
Der Einfluss von HB 419--einem neuen oralen Antidiabeticum--auf den Fettstoffwechsel.